Department of Dermatology, Mayo Clinic, Scottsdale, Arizona, USA.
Dermatol Surg. 2012 Oct;38(10):1582-603. doi: 10.1111/j.1524-4725.2012.02574.x. Epub 2012 Sep 7.
The appropriate use criteria process synthesizes evidence-based medicine, clinical practice experience, and expert judgment. The American Academy of Dermatology in collaboration with the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery has developed appropriate use criteria for 270 scenarios for which Mohs micrographic surgery (MMS) is frequently considered based on tumor and patient characteristics. This document reflects the rating of appropriateness of MMS for each of these clinical scenarios by a ratings panel in a process based on the appropriateness method developed by the RAND Corp (Santa Monica, CA)/University of California-Los Angeles (RAND/UCLA). At the conclusion of the rating process, consensus was reached for all 270 (100%) scenarios by the Ratings Panel, with 200 (74.07%) deemed as appropriate, 24 (8.89%) as uncertain, and 46 (17.04%) as inappropriate. For the 69 basal cell carcinoma scenarios, 53 were deemed appropriate, 6 uncertain, and 10 inappropriate. For the 143 squamous cell carcinoma scenarios, 102 were deemed appropriate, 7 uncertain, and 34 inappropriate. For the 12 lentigo maligna and melanoma in situ scenarios, 10 were deemed appropriate, 2 uncertain, and 0 inappropriate. For the 46 rare cutaneous malignancies scenarios, 35 were deemed appropriate, 9 uncertain, and 2 inappropriate. These appropriate use criteria have the potential to impact health care delivery, reimbursement policy, and physician decision making on patient selection for MMS, and aim to optimize the use of MMS for scenarios in which the expected clinical benefit is anticipated to be the greatest. In addition, recognition of those scenarios rated as uncertain facilitates an understanding of areas that would benefit from further research. Each clinical scenario identified in this document is crafted for the average patient and not the exception. Thus, the ultimate decision regarding the appropriateness of MMS should be determined by the expertise and clinical experience of the physician.
适当使用标准流程综合了循证医学、临床实践经验和专家判断。美国皮肤病学会与美国莫氏外科学会、美国皮肤外科学会协会和美国莫氏外科学会合作,根据肿瘤和患者特征,为莫氏显微外科手术(MMS)经常被考虑的 270 种情况制定了适当使用标准。本文反映了一个由评级小组根据 RAND 公司(加利福尼亚州圣莫尼卡/加州大学洛杉矶分校)开发的适当性方法进行的基于流程的 MMS 对这些临床情况的适当性进行评级的结果。在评级过程结束时,评级小组对所有 270 个(100%)场景达成了共识,其中 200 个(74.07%)被认为是适当的,24 个(8.89%)是不确定的,46 个(17.04%)是不适当的。对于 69 个基底细胞癌场景,53 个被认为是适当的,6 个不确定,10 个不适当。对于 143 个鳞状细胞癌场景,102 个被认为是适当的,7 个不确定,34 个不适当。对于 12 个恶性黑色素瘤和原位黑色素瘤场景,10 个被认为是适当的,2 个不确定,0 个不适当。对于 46 个罕见皮肤恶性肿瘤场景,35 个被认为是适当的,9 个不确定,2 个不适当。这些适当使用标准有可能影响医疗保健的提供、报销政策和医生对 MMS 患者选择的决策,并旨在优化 MMS 在预期临床获益最大的情况下的使用。此外,对被评为不确定的场景的认识有助于理解那些需要进一步研究的领域。本文档中确定的每个临床场景都是为一般患者设计的,而不是例外情况。因此,MMS 是否适当的最终决定应由医生的专业知识和临床经验来决定。